RxDoctor Payments Data

Ryan Bradley Ortizo, MD

Family Medicine · Colton, CANPI 1083173348

Payments from drug & device makers

$2,521in general payments, 2019–2025

Across 27 payments — averaging $93.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$744
  • Phathom Pharmaceuticals, Inc.$250
  • Bayer$246
  • Boehringer Ingelheim$240
  • Corcept Therapeutics$184
  • Intra-sana Laboratories$125
  • plus $732 from 9 others

What the payments were for

  • Food & beverage$2,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,521 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$17,050
Medicare patients
49
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$93,775
JardianceEmpagliflozin67$84,280
TrulicityDulaglutide40$65,874
EliquisApixaban83$62,305
FarxigaDapagliflozin Propanediol70$53,557
JanuviaSitagliptin Phosphate17$28,131
KerendiaFinerenone29$25,097
XareltoRivaroxaban28$23,265
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,653
Humulin R U-500 KwikpenInsulin Regular, Human12$13,859
Janumet XrSitagliptin Phos/Metformin Hcl14$11,898
TradjentaLinagliptin12$9,797
Atorvastatin Calcium621$6,153
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$5,650
Levemir FlexpenInsulin Detemir31$5,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$240$94,07679 claims
Lilly USA, LLCTrulicity$33$65,87440 claims
PfizerEliquis$15$62,30583 claims
AstraZenecaFarxiga$744$53,55770 claims
BayerKerendia$246$25,09729 claims
GSKTrelegy Ellipta$111$15,65322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →